Advances in the management of colorectal cancer: from biology to treatment

Ahmed, Shahid; Johnson, Kate; Ahmed, Osama; Iqbal, Nayyer

doi:10.1007/s00384-014-1928-5

Cited by 77 publications

(65 citation statements)

References 121 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This is supported by the finding of a sharp increase in the percentage of bowel cancer lesions observed during the years after the introduction of screening colonoscopy (18). On the other hand, treatment advances have had a major impact (19,20) which may explain the pronounced decline in mortality in the absence of a decrease in incidence in the age groups under 55 years.…”

Section: Potential Role Of Other Factorsmentioning

confidence: 90%

Declining Bowel Cancer Incidence and Mortality in Germany: An Analysis of Time Trends in the First Ten Years After the Introduction of Screening Colonoscopy

Brenner¹,

Schrotz‐King

Holleczek

et al. 2016

Deutsches Ärzteblatt International

View full text Add to dashboard Cite

show abstract

Section: Potential Role Of Other Factorsmentioning

confidence: 90%

Declining Bowel Cancer Incidence and Mortality in Germany: An Analysis of Time Trends in the First Ten Years After the Introduction of Screening Colonoscopy

Brenner¹,

Schrotz‐King

Holleczek

et al. 2016

Deutsches Ärzteblatt International

View full text Add to dashboard Cite

show abstract

“…Colorectal cancer (CRC) is the third most common malignancy worldwide and the fourth leading cause of cancer-related deaths globally [1]. Although great advances in chemotherapy and radiotherapy in recent decades have reduced the recurrence and improved survival of CRC, 136 830 new cases were diagnosed and 50 310 deaths attributed to CRC in 2014.…”

Section: Introductionmentioning

confidence: 99%

Lipocalin2 suppresses metastasis of colorectal cancer by attenuating NF-κB-dependent activation of snail and epithelial mesenchymal transition

Feng

Chen

et al. 2016

Mol Cancer

View full text Add to dashboard Cite

BackgroundLipocalin2 (LCN2) is a secretory protein that is aberrantly expressed in several types of cancer and has been involved in metastatic progression. However, neither mechanisms nor the role that LCN2 plays in the metastasis of colorectal cancer are clear.MethodsLCN2 expression in colorectal cancer was detected by immunohistochemistry in 400 tissue specimens and Kaplan-Meier survival analysis was performed. In vitro, real-time PCR, western blot, colony formation assay, immunofluorescence assay, wound healing assay, migration and invasion experiment were performed to investigate the effects of LCN2 in epithelial mesenchymal transition (EMT), migration and invasion, respectively. In vivo mouse xenograft and metastasis models were utilized to determine tumorigenicity and metastasis ability, and immunohistochemistry, real-time PCR, western blot were used to evaluate the related protein expression. Luciferase reporter assay was used to explore the role of LCN2 on NF-ĸB promoter.ResultsLCN2 was highly expressed in 66.5% of the specimens, and significantly correlated with positive E-cadherin in the membrane and negative nuclear β-catenin. Higher expression of LCN2 together with negative NF-κB expression was negatively related to nuclear accumulation of snail and predicted favorable prognosis. LCN2 blocked cell proliferation, migration and invasion in vitro and in vivo, and inhibited translocation of NF-κB into nucleus. NF-κB could reverse the effect of LCN2 on EMT and promote snail expression. Rescued snail expression had similar effect without influencing NF-κB activity.ConclusionLCN2 may be an important negative regulator in EMT, invasion and metastasis of CRC via acting as upstream of NF-κB/snail signaling pathway. Thereby combinative manipulation of LCN2 and NF-κB/snail pathway may represent a novel and promising therapeutic approach for the patients with CRC.Electronic supplementary materialThe online version of this article (doi:10.1186/s12943-016-0564-9) contains supplementary material, which is available to authorized users.

show abstract

“…Colon cancer is a common malignant tumor of the gastrointestinal tract and is the fourth leading cause of cancer-associated mortality (1). The 5-year survival rate of patients with colon cancer is 50% (1,2). The onset of colon cancer is associated with genetic and environmental factors (e.g., exposure to carcinogens and smoking) (3).…”

Section: Introductionmentioning

confidence: 99%

Wnt6 contributes tumorigenesis and development of colon cancer via its effects on cell proliferation, apoptosis, cell‑cycle and migration

Zheng

2018

Oncol Lett

View full text Add to dashboard Cite

Wnt proteins have been reported to contribute to the progression of various types of cancer. Wnt6 is a member of the Wnt family and may promote tumorigenesis in gastrointestinal cancer and cervical cancer. In the present study, the expression of Wnt6 in human colon cancer cell lines was evaluated, in order to investigate the role of Wnt6 in the development of colon cancer. Additionally, the effects of Wnt6 upregulation or downregulation on proliferation, apoptosis, cell cycle and cell migration of colon cancer cells have been investigated. Furthermore, western blot analysis was employed to evaluate the expression of Wnt6, B-cell lymphoma 2-associated X protein (Bax), caspase-3 and matrix metalloproteinase (MMP)2. The results of the present study demonstrated that the expression of Wnt6 was increased in HCT116 and SW480 cells compared with the remaining colon cancer cell lines. Furthermore, overexpression Wnt6 resulting from transfection of pGPU6/GFP/Neo-Wnt6-Homo-1 plasmid promoted the proliferation, cell cycle and migration of HCT116 and SW480 cells, but inhibited cell apoptosis . The expression of caspase-3 and MMP2 was increased, whereas the expression of Bax was decreased in response to upregulation of Wnt6. These results suggested that Wnt6 may serve a vital function in the development of colon cancer.

show abstract

Advances in the management of colorectal cancer: from biology to treatment

Abstract: Over the past decade, there has seen substantial progress in our understanding of and in the management of CRC.

Cited by 77 publications

References 121 publications

Declining Bowel Cancer Incidence and Mortality in Germany: An Analysis of Time Trends in the First Ten Years After the Introduction of Screening Colonoscopy

Declining Bowel Cancer Incidence and Mortality in Germany: An Analysis of Time Trends in the First Ten Years After the Introduction of Screening Colonoscopy

Lipocalin2 suppresses metastasis of colorectal cancer by attenuating NF-κB-dependent activation of snail and epithelial mesenchymal transition

Wnt6 contributes tumorigenesis and development of colon cancer via its effects on cell proliferation, apoptosis, cell‑cycle and migration

Contact Info

Product

Resources

About